- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT ...
Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. The exudative or ‘wet’ form of the disease is characterized by the growth of abnormal blood vessels from ...
REDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
PITTSBURGH, May 8, 2025 /PRNewswire/ -- Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today held an oral ...
Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company’s approach to AAV ...
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback